186203-08-7 Usage
Chemical class
Pyrrolidine carboxylic acids
Molecular weight
305.28 g/mol
Building block in organic synthesis
Used in the creation of complex organic molecules
Medicinal chemistry application
Utilized in the development of bioactive molecules
Trifluoromethyl group
Imparts unique physicochemical properties
Drug design and discovery
Valuable for creating new pharmaceutical compounds
Benzyl group
Contributes to pharmacological potential
Pyrrolidine ring
Contributes to pharmacological potential
Therapeutic applications
Potential use in treating various diseases and conditions
Importance in pharmaceutical research and development
Promising for creating new and effective treatments
Check Digit Verification of cas no
The CAS Registry Mumber 186203-08-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,6,2,0 and 3 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 186203-08:
(8*1)+(7*8)+(6*6)+(5*2)+(4*0)+(3*3)+(2*0)+(1*8)=127
127 % 10 = 7
So 186203-08-7 is a valid CAS Registry Number.
186203-08-7Relevant academic research and scientific papers
ALKYNYL QUINAZOLINE COMPOUNDS
-
Paragraph 1046, (2021/02/19)
The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.
Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4- trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones
Fukui, Hideto,Shibata, Tetsuo,Naito, Takanobu,Nakano, Jun,Maejima, Tetsuro,Senda, Hisato,Iwatani, Wakao,Tatsumi, Yoshiyuki,Suda, Masahiro,Arika, Tadashi
, p. 2833 - 2838 (2007/10/03)
The titled compounds were synthesized and evaluated for in vitro antibacterial activity. The (3R,4S)3-aminomethyl-4-trifluoromethyl derivative (S-34109) was confirmed to be optimal because of its superior activity against quinolone and methicillin-resistant Staphyrococcus aureus and low side effect potential.
